Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)
The Journal of Clinical Endocrinology & Metabolism · 17.06.2024 · 109 (7) · 1745-1753
DOI: 10.1210/clinem/dgae038 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 22.01.2024. Verfasst von Juan P Frias und 6 weiteren Autor:innen. Beteiligte Einrichtung: Velocity Clinical Research, Los Angeles, CA 90057, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Context
In previous SURPASS studies tirzepatide reduced hemoglobin glycated A1c (HbA1c) and body weight and improved markers of insulin sensitivity and β-cell function to a greater extent than comparators.
Objective
Explore changes in biomarkers of β-cell function and insulin sensitivity and in efficacy profiles in baseline biomarker quartile analyses with tirzepatide compared to semaglutide.
Design
Post hoc analysis of SURPASS-2 phase 3 trial (participants randomly assigned to receive weekly subcutaneous tirzepatide or semaglutide for 40 weeks).
Setting
Post hoc analysis of 128 sites in 8 countries.
Participants
A total of 1879 participants with type 2 diabetes.
Interventions
Once-weekly tirzepatide (5, 10, 15 mg) or semaglutide 1 mg. Main outcomes measures Change in homeostatic model assessment indices for pancreatic β-cell function (HOMA2-B) and for insulin resistance (HOMA2-IR), fasting glucagon, fasting C-peptide, and fasting insulin.
Results
At week 40, a greater increase in HOMA2-B was seen with tirzepatide (5, 10, 15 mg) doses (96.9-120.4%) than with semaglutide 1 mg (84.0%) (P < .05). There was a greater reduction in HOMA2-IR with all doses of tirzepatide (15.5%-24.0%) than with semaglutide 1 mg (5.1%) (P < .05). Tirzepatide 10 and 15 mg resulted in a significant reduction in both fasting C-peptide (5.2%-6.0%) and fasting glucagon (53.0%-55.3%) compared with an increase of C–peptide (3.3%) and a reduction of glucagon (47.7%) with semaglutide 1 mg (P < .05). HbA1c and body weight reductions were greater with all tirzepatide doses than semaglutide within each HOMA2-B and HOMA2-IR baseline quartile.
Conclusion
In this post hoc analysis, improvements in HbA1c and weight loss were consistent and significantly higher with tirzepatide, regardless of baseline β-cell function and insulin resistance, compared with semaglutide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Velocity Clinical Research, Los Angeles, CA 90057, USA.
- Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, University of Antwerp, 2650 Edegem, Belgium.
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
- TechData Service, King of Prussia, PA 19406, USA.
- Lilly Research Laboratories, Eli Lilly and Company, San Juan 00918, Puerto Rico.
ORCID-Profile: Melissa K Thomas, Juan M Maldonado
Förderung
- Eli Lilly and Company
Zitieren
APA
Frias, J. P., De Block, C., Brown, K., Wang, H., Thomas, M. K., Zeytinoglu, M., & Maldonado, J. M. (2024). Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). The Journal of Clinical Endocrinology & Metabolism, 109(7), 1745-1753. https://doi.org/10.1210/clinem/dgae038
Vancouver
Frias JP, De Block C, Brown K, Wang H, Thomas MK, Zeytinoglu M, et al. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). The Journal of Clinical Endocrinology & Metabolism. 2024;109(7):1745-1753. doi:10.1210/clinem/dgae038
BibTeX
@article{Frias2024,
author = {Frias, Juan P and De Block, Christophe and Brown, Katelyn and Wang, Hui and Thomas, Melissa K and Zeytinoglu, Meltem and Maldonado, Juan M},
title = {Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {7},
pages = {1745--1753},
doi = {10.1210/clinem/dgae038}
}
EUVIMED